Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diabetes Therapy
Lisinopril plus telmisartan may prevent diabetic nephropathy type 2 diabetes, hypertension
April 10th, 2006
Lisinopril plus telmisartan may provide a new approach to diabetic nephropathy prevention in patients with type 2 diabetes, hypertension and microalbuminuria. "Angiotensin-converting enzyme (ACE) inhibitors have favorable effects on hypertension and diabetic nephropathy, but persistent use may result in incomplete blockade of the renin-angiotensin system. Long-term effects of dual blockade using the ACE inhibitor lisinopril and the long-acting angiotensin H receptor blocker (ARB) telmisartan on blood pressure and albumin excretion rate (AER) were evaluated," researchers in Turkey report. In the present study, A.M. Sengul and colleagues, Sisli Erfal...
Source: Diabetes Week (2006-04-10)
|
